News

According to the company, the patent will provide exclusivity for Pulmaquin until 22 October 2027. Pulmaquin is a dual release formulation that is a mixture of a liposomal

Melt Extrusion and Calendering Line will help pharmaceutical manufacturers procure extrusion, calendering and cooling equipment from one supplier, packagingeurope.com reported. Melt extrusion, which is a method for drug

The approval allows the company to use VibeX with its KXL system for treating corneal ectasia. Avedro CEO David Muller said this second orphan drug designation and the

The launch follows a settlement with Teva Women’s Health. The global marketing research company for the pharmaceutical industry, IMS Health said Watson is the first applicant to submit

BOLERO-2 (Breast cancer trials of OraL EveROlimus-2), a Phase III, randomized, double-blind, placebo-controlled, multicenter study was devised to assess the safety and efficacy of everolimus in combination with

The patent covers pharmaceutical compositions of a DNA cross-linker (stabilized active metabolite of ifosfamide), including palifosfamide (Zymafos or ZIO-201) and their use in treating cancer. The company has

The trial evaluated the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme’s Enhanze technology in hereditary angioedema (HAE). Enhanze technology is a drug

Cegedim Relationship Management’s REMS compliance solution includes compliance consulting, customer outreach, data analytics and a campaign management platform. According to the company, REMS are risk management plans that

According to Sacbee, the companies marketing over-the counter (OTC) HCG products were issued seven warning Letters by FDA and FTC. There are no FDA-approved HCG drug products for